Is third trimester XXXX reuptake inhibitor use associated with postpartum @entity548 ?

@entity1 @entity548 @entity190 @entity1316 @entity750 @entity2981
UNASSIGNED: As @entity750 reuptake inhibitor (SRI) use may decrease platelet function, previous research has shown a relationship between SRI use and an increased risk for @entity2981 and @entity548 . The literature regarding the association between SRI use during pregnancy and increased @entity548 at delivery, referred to as postpartum @entity548 (PPH), is mixed. In secondary analyses from two prospective observational studies of pregnant @entity1 with @entity1316 , 263 @entity1 were exposed to an SRI (n  =  51) or not (n  =  212) in the third trimester. To be precise, we used the terminology estimated @entity190 (EBL) >600  cc rather than the term PPH because the current definition of PPH differs. The occurrence of EBL >600  cc was determined using the Peripartum Events Scale (PES) completed from obstetrical records by a blinded medically trained member of the study team. EBL >600  cc occurred in 8.7% of @entity1 in this cohort. There was no statistically significant difference in the rates of EBL >600  cc in the 24  h after delivery in @entity1 taking SRIs during the third trimester (9.8%) compared to non-exposed @entity1 (8.5%). Utilizing generalizing estimating equations, the odds of EBL >600  cc in each group were not significantly different (OR 1.17, CI-0.41-3.32, p  =  0.77). When the SRI group was limited to @entity1 with exposure at the time of delivery, the difference in the odds of EBL >600  cc was unchanged (OR 1.16, CI  =  0.37-3.64, p  =  0.79). In population, both third trimester and use at delivery of SRIs during pregnancy was not associated with an increased risk of excessive @entity190 .
